AFP levels alone are elevated in only two-thirds of HCC patients, and false positives occur frequently in individuals with other liver conditions, limiting AFP’s standalone utility (Y. T. Lee et al. 2021b). This evidence concerns the gene AFP and hepatocellular carcinoma.